Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1698336 | 0.98 | NPSR1 (1.00) | NPSR1SMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL2097679 | 0.98 | NPSR1 (1.00) | NPSR1SMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL2091358 | 0.98 | NPSR1 (1.00) | NPSR1SMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL2092328 | 0.96 | NPSR1 (0.89) | NPSR1SMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL2090052 | 0.91 | — | — | |
| SCHEMBL14492244 | 0.84 | NPSR1 (0.70) | NPSR1SMN1; SMN2ALDH1A1KMT2AEPHX1 | |
| SCHEMBL12425654 | 0.84 | NPSR1 (0.70) | NPSR1SMN1; SMN2ALDH1A1KMT2AEPHX1 | |
| SCHEMBL22651967 | 0.84 | NPSR1 (0.70) | NPSR1SMN1; SMN2HPGDALDH1A1KMT2A | |
| Carbamic Acid SCHEMBL11200157 | 0.84 | NPSR1 (0.70) | NPSR1SMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL13130101 | 0.84 | NPSR1 (0.70) | NPSR1SMN1; SMN2HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728235-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-10023541-B2 | Urea compounds and their use as enzyme inhibitors | BIAL-PORTELA & CA, S.A. (PT) | 2018-07-17 | — | — | US | disclosed |
| US-10023541-B2 | Urea compounds and their use as enzyme inhibitors | BIAL-PORTELA & CA, S.A. (PT) | 2018-07-17 | — | — | US | disclosed |
| EP-2986604-B1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170101381-A1 | UREA COMPOUNDS AND THEIR USE AS ENZYME INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2017-04-13 | — | — | US | disclosed |
| US-20170101381-A1 | UREA COMPOUNDS AND THEIR USE AS ENZYME INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2017-04-13 | — | — | US | disclosed |
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| WO-2014170197-A1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-23 | — | — | WO | disclosed |
| EP-2170850-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2014-09-24 | — | — | EP | disclosed |
| US-8809341-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809539-B2 | Dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809539-B2 | Dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-1654257-B1 | AMINOPYRONES AND THEIR USE AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008152149-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2008-12-18 | — | — | WO | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023541-B2 | Urea compounds and their use as enzyme inhibitors | ACHE, GAA, GYS2 | NPSR1 779/4885SMN1; SMN2 78/4885HPGD 3134/4885 |
| US-20170101381-A1 | UREA COMPOUNDS AND THEIR USE AS ENZYME INHIBITORS | ACHE, GAA, GYS2 | NPSR1 779/4885SMN1; SMN2 78/4885HPGD 3134/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | NPSR1 202/4885SMN1; SMN2 3787/4885HPGD 1951/4885 |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR2, S1PR5 | NPSR1 468/4885SMN1; SMN2 3276/4885HPGD 1618/4885 |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | NPSR1 4094/4885SMN1; SMN2 2043/4885HPGD 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.